Clinical Epidemiology

Age, Race, Diabetes, Blood Pressure, and Mortality among Hemodialysis Patients

Orrin B. Myers, Christopher Adams, Mark R. Rohrscheib, Karen S. Servilla, Dana Miskulin, Edward J. Bedrick and Philip G. Zager
JASN November 2010, 21 (11) 1970-1978; DOI: https://doi.org/10.1681/ASN.2010010125

Abstract

Observational studies involving hemodialysis patients suggest a U-shaped relationship between BP and mortality, but the majority of these studies followed large, heterogeneous cohorts. To examine whether age, race, and diabetes status affect the association between systolic BP (SBP; predialysis) and mortality, we studied a cohort of 16,283 incident hemodialysis patients. We constructed a series of multivariate proportional hazards models, adding age and BP to the analyses as cubic polynomial splines to model potential nonlinear relationships with mortality. Overall, low SBP associated with increased mortality, and the association was more pronounced among older patients and those with diabetes. Higher SBP associated with increased mortality among younger patients, regardless of race or diabetes status. We observed a survival advantage for black patients primarily among older patients. Diabetes associated with increased mortality mainly among older patients with low BP. In conclusion, the design of randomized clinical trials to identify optimal BP targets for patients with ESRD should take age and diabetes status into consideration.

Studies of the general population have consistently demonstrated the benefits of aggressive antihypertensive therapy.1–4 Published guidelines for the treatment of hypertension have been widely circulated and applied to heterogeneous patient groups5,6; however, the risks associated with hypertension vary considerably across patients. The majority of patients with hypertension experience normal health and longevity.2 Some studies indicated that age, race, and diabetes status may influence the relationship between BP and clinical outcomes.7 There is a U-shaped relationship between BP and mortality among patients who are older than 85 years. The very old may be at increased risk from aggressive antihypertensive therapy.8 A given increase in BP may carry a higher risk for adverse outcomes among black versus white individuals.9 On the basis of results of several studies, including Action in Diabetes and Vascular Disease: Preterax and Diamacron MR Controlled Evaluation (ADVANCE)10 and Steno type 2,11 the American Heart Association and the American Diabetes Association have issued guidelines calling for lower BP targets among patients with versus without diabetes.5,6,12

Among hemodialysis (HD) patients, observational studies have often demonstrated a U-shaped relationship between BP and mortality13–15; however, the majority of these studies were conducted in large, heterogeneous cohorts of HD patients. This study explored the hypothesis that the relationship between BP and mortality among incident HD patients is modified by age, race, and diabetes status.

RESULTS

The study cohort consisted of 16,283 incident HD patients with 32,042 person-years of follow-up (median 1.5 years). There were 6250 deaths. Demographics of the study cohort are shown in Table 1. Diabetes was the cause of ESRD in 36.1, 56.7, and 40.4% of patients who were aged <50, 50 to 69, and ≥70 years, respectively. The ages of patients with and without diabetes were similar. White patients (64.8 ± 14.4 years) were older than black patients (57.3 ± 14.9 years). Isolated systolic hypertension was more common among patients with versus without diabetes (P < 0.001). Combined systolic and diastolic hypertension was more common among black versus white patients. Isolated diastolic hypertension was uncommon (≤0.3%).

View this table:
Table 1.

Demographic characteristics of incident HD study patients and BP during days 31 to 120 of treatment

Combined Effects of Systolic and Diastolic BP on Mortality

Hazard ratios (HRs) for mortality risks, associated with increasing levels of systolic BP (SBP) at given diastolic BP (DBP) values are shown in Figure 1. Mortality associated with a given SBP tended to increase as DBP rose (P < 0.001, SBP × DBP interaction). Low SBP levels were associated with increased mortality over the range of DBP. Regardless of DBP, increasing levels of SBP, up to 180 mmHg, were not associated with increased mortality. The addition of DBP to models that already contained SBP increased rather than decreased the Δ Bayesian Information Criterion (ΔBIC; Table 2); therefore, SBP was much stronger than DBP as a predictor of mortality. Although DBP parameters may have a statistically significant relationship to mortality, its clinical impact seems to be modest.

Figure 1.
Figure 1.

Analysis of the combined association of predialysis SBP and DBP on mortality in incident HD patients reveals that mortality was greater at lower versus higher SBP. Model adjusted for age; gender; race; cause of ESRD; and time-varying serum albumin, hemoglobin, creatinine, dialysis dosage, and postdialysis weight. Referent: SBP = 140 mmHg, DBP = 80 mmHg.

View this table:
Table 2.

Relative fit of models for predicting mortality of incident HD patients

Age, BP, and Mortality

The relationship between SBP and mortality varied with age (P < 0.001; Figure 2A). Among patients who were older than 50 years, SBP <140 mmHg was associated with an increased mortality. SBP values >160 mmHg were not associated with increased mortality. Among patients who were younger than 50 years, SBP values <140 mmHg were not associated with increased mortality, and values >160 mmHg were associated with increased mortality. Low DBP values were associated with an increased mortality only among older patients (P < 0.001; Figure 2B). The relationship among pulse pressure (PP), age, and mortality (Figure 2C) was similar to that of SBP. Older patients with low PP had the highest mortality.

Figure 2.
Figure 2.

Age interacts with BP so that (A) mortality among incident HD patients is highest for older patients with lower SBP. Only patients <40 years old have increased mortality risk with increasing SBP. (B) Mortality is highest for older patients with lower DBP. (C) Mortality risk and PP show higher mortality risk for older patients with low PP. Models adjusted for age; gender; race; cause of ESRD; and time-varying serum albumin, hemoglobin, creatinine, dialysis dosage, and postdialysis weight. Error bars are point-wise 95% CIs. Referent: SBP = 140 mmHg, DBP = 80 mmHg, PP = 73 mmHg.

Race, BP, and Mortality

Overall, black patients had lower mortality than white patients (HR 0.70 [95% confidence interval [CI] 0.59 to 0.82] at 150 mmHg SBP; Figure 3, A and B). Race did not significantly modify the relationships of either SBP or DBP with mortality. Curves representing the HRs at different levels of SBP among black and white patients were nearly parallel except at lowest levels of SBP (Figure 3A). The relationships between DBP and mortality were similar among black and white patients (Figure 3B).

Figure 3.
Figure 3.

Black incident HD patients have lower mortality risk than white patients across all SBP and DBP (A and B), and diabetic patients have increased mortality risk when SBP <140 mmHg (C and D). Models adjusted for age; gender; race; cause of ESRD; and time-varying serum albumin, hemoglobin, creatinine, dialysis dosage, and postdialysis weight. Error bars are point-wise 95% CIs. Referent: SBP = 140 mmHg, DBP = 80 mmHg.

Diabetes, BP, and Mortality

The greater mortality among patients with versus without diabetes was largely restricted to those with SBP <140 mmHg (P < 0.001; Figure 3C). In contrast, among patients with SBP >140 mmHg, mortality was similar among patients with and without diabetes. The diagnosis of diabetes also modified the relationship between DBP and mortality (P = 0.001; Figure 3D).

We conducted sensitivity analyses to ascertain whether the mortality, SBP, and diabetes association was affected by increasing the lag between events/censoring and the time-varying covariate window from 30 to 90 days. This reduced the number of eligible patients by 590 and the number of events by 261; however, the relationship among diabetes, SBP, and mortality was similar using either the 30- or 90-day lag (data not shown).

Joint Association of Race, BP, and Age with Mortality

Among patients who were older than 40 years, mortality at any given SBP was lower among black versus white patients. In contrast, among patients who were younger than 40 years, mortality was similar among black and white patients at any given SBP (P < 0.001; Figure 4, A through C); however, the percentage of patients with SBP <120 mmHg was smaller among black (3.6%) versus white (7.1%) patients. Although statistically significant, the clinical relevance of the effect was modest, as reflected in the 86-unit increase in ΔBIC value over the SBP × age model (Table 2).

Figure 4.
Figure 4.

A survival advantage for black versus white incident HD patients exists for patients over 40 years across all SBP but not for younger patients (A through C). Diabetic patients over age 40 with lower SBP (<140 mmHg) have increased mortality relative to nondiabetic patients (D through F). The relationships between SBP and mortality among younger diabetic versus nondiabetic patients are similar. Models adjusted for gender; race; cause of ESRD; and time-varying serum albumin, hemoglobin, creatinine, dialysis dosage, and postdialysis weight. Error bars are point-wise 95% CIs. Referent: SBP = 140 mmHg and age shown in each panel.

Joint Association of Diabetes, BP, and Age with Mortality

Among younger patients, the relationships of SBP with mortality were similar among patients with and without diabetes (Figure 4, D through F); however, with increasing age, the mortality risk associated with low SBP was greater among patients with versus without diabetes (P < 0.001). The mortality risk associated with higher SBP levels was similar among patients with and without diabetes in all age groups. Although statistical tests indicated that the association among SBP, age, and mortality was modified by diabetes and race, the ΔBIC values for these models were 77 and 95, respectively (Table 2), suggesting that models this complex may not be needed to predict mortality. The model with the smallest BIC was the diabetes × SBP + age model (Figure 3C). Two other models had ΔBIC within 10 units (SBP × age [Figure 2A] and SBP + age) of this model, and another four models had ΔBIC values within 27 to 53 units.

DISCUSSION

This study is in concert with previous reports that described an association between low SBP and increased mortality among HD patients.13–15 It extends previous observations by demonstrating (1) that the increased mortality associated with low SBP was more pronounced among older patients and those with diabetes; (2) high SBP values among younger patients were associated with increased mortality, regardless of race or diabetes status; (3) among older patients, higher SBP values were not associated with increased mortality; and (4) increased mortality among white versus black patients was largely confined to older patients.

In this study, SBP was more powerful than DBP as a predictor of mortality. This finding is in concert with the greater predictive power of SBP in the general population16; however, our results are in contrast to a report by Bakris et al., 17 which demonstrated that the inclusion of DBP in a model containing SBP informed the risk for future mortality among patients with type 2 diabetes in the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study. Recently, Agarwal18 reported that the addition of DBP to models containing SBP significantly improved the prediction of all-cause mortality among patients with chronic kidney disease (CKD). Although we found an association between DBP and mortality, it was quantitatively much less than that between SBP and mortality. The following factors may have contributed to these disparate findings: (1) Agarwal studied patients who had CKD and had not yet reached ESRD; (2) women composed only 4% of his study cohort; and (3) the covariates differed significantly.

Age, BP, and Mortality

The relationship between SBP and mortality among HD patients resembles that of older patients in the general population19; however, the relationship of BP to mortality was not uniform across age groups, suggesting that among HD patients, optimal BP targets may differ by age. Only in the youngest cohort (30-year-olds) of HD patients studied was the relationship of SBP to mortality similar to that observed in the general population.20,21 Thereafter, each 10-year increment in age was accompanied by an increase in the HR for mortality associated with low SBP and attenuation of the HR for mortality associated with hypertension. High SBP values were associated with increased mortality only among younger patients. Among HD patients who were older than 40 years, isolated systolic hypertension similar to that seen in the elderly general population was common. This may reflect the presence of accelerated atherosclerosis and arteriosclerosis, which are common among HD patients. Previous studies conducted of HD patients demonstrated that hypertension was associated with increased mortality among those who survived the first 3 years of dialysis.14,22

The association of low SBP with mortality among HD patients is in concert with observations in the general population,8 patients with CKD,23 and patients with heart failure.24 The reasons for this relationship among HD patients may be multifactorial. Untreated patients with low to normal BP may have severe cardiac disease.25 Patients with low to normal BP may have significant intradialytic reductions in myocardial perfusion during HD.26,27 Elderly patients and patients with diabetes, with stiff, noncompliant vessels and occlusive arterial disease, may experience significant reductions in organ perfusion during dialysis.

The commonly observed U-shaped relationship between SBP and mortality among HD patients may reflect the wide age spread of patients in our study cohort. Among younger patients, there is a reverse L-shaped curve, reflecting the increased mortality associated with high SBP. In contrast, among older patients, there is an L-shaped curve, reflecting increased mortality at lower SBP values. Middle-aged patients may exhibit either pattern or a U-shaped curve. Combining all age groups results in the commonly cited U-shaped curve.13,15

Diabetes, BP, and Mortality

We observed effect modification of diabetes status on the relationship between SBP and mortality. The increase in mortality among patients with diabetes was largely restricted to patients with SBP <140 mmHg. The observed interaction related mainly to the higher mortality among patients who had diabetes with SBP <140 mmHg; however, low SBP values were also associated with increased mortality among HD patients without diabetes. Age, therefore, was the only analyzed variable that was associated with a qualitative change in the shape of the association curves between SBP and mortality.

Reasons for the increased mortality with low SBP among patients with versus without diabetes include the following: (1) Diabetes is associated with the aging process28–30 such that HD patients who have diabetes and are of a given age may experience an increase in the mortality associated with low SBP comparable to that experienced by older HD patients without diabetes; (2) patients with diabetes may not tolerate low SBP as well as patients without diabetes do; (3) patients with diabetes and low SBP may have more comorbidities than patients without diabetes. Ishida et al.31 reported that after dialysis, the reduction in middle cerebral arterial flow in response to a tilt test is much greater among patients with versus without diabetes. Nevertheless, current clinical guidelines for patients without ESRD recommend lower BP targets for patients with diabetes5,6,12,32; however, we are not aware of published guidelines that call for different BP goals for HD patients with versus without diabetes. Unfortunately, the optimal BP targets in both patients with and without diabetes and with CKD have not been defined. Follow-up data from the Modification of Diet in Renal Disease (MDRD) study demonstrated that a 32% reduction in risk for ESRD associated with lower than usual BP among patients with nondiabetic CKD.33 In contrast, both the African American Study of Kidney Disease and Hypertension (AASK) and Remipril Efficacy in Nephropathy (REIN-2) trials failed to demonstrate that intensive BP control slows the progression of nondiabetic CKD. Moreover, in Action to Control Cardiovascular Risk in Diabetes (ACCORD), intensive control of BP among patients with type 2 diabetes failed to reduce the annual rate of the primary outcome, a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes.34

Race, BP, and Mortality

The observation that the lower mortality among black versus white patients was primarily restricted to older patients warrants further investigation. Several studies have noted an apparent paradox among black patients who are on dialysis. Despite lower values for dialysis dosage (single-pool Kt/V) and hemoglobin, mortality is lower among black versus white patients.35–38 In this study, black patients had lower mortality than white patients despite having higher BP values. Parekh et al.39 showed that, among dialysis patients, white patients had a higher risk for atherosclerotic cardiovascular disease; therefore, underlying atherosclerotic cardiovascular disease may be an important confounder, which may contribute to lower BP and increased mortality among white HD patients. Bellasi et al.,40 however, found no significant differences in aortic pulse wave velocity, augmentation index, and coronary and thoracic arterial calcification scores, respectively, between black and white patients with ESRD.

Should Mild to Moderate Hypertension Be Treated in HD Patients?

In this study, the relationship between SBP and mortality among HD patients resembles that of much older patients in the general population19; however, the relationship of BP to mortality was not uniform across age groups, suggesting that among HD patients, optimal BP targets may differ by age. Only in the youngest cohort (30-year-olds) of HD patients studied did the curvilinear relationship between SBP and mortality resemble that observed in the general population20,21; however, even among young HD patients, the increase in mortality risk associated with increases in SBP was significantly less steep than that observed in the general population, as reported in a meta-analysis conducted by the Prospective Studies Collaboration.41

No large randomized, controlled trials targeting tight versus usual control of BP, powered for mortality, have been conducted of HD patients. Recently Heerspink et al.42 conducted a meta-analysis of randomized, controlled trials that assessed the effect of different antihypertensive medications on all-cause mortality, cardiovascular mortality, and cardiovascular events among HD patients. The majority of patients had only modest hypertension, and the average baseline SBP ranged from 134 to 155 mmHg. Nevertheless, antihypertensive therapy was associated with significant reductions in mortality and cardiovascular events, even though the absolute reductions in BP were small; therefore, at least a portion of the observed beneficial effect may be attributed to medication rather than a reduction in BP.

The Study of Isolated Systolic Hypertension in the Elderly demonstrated that treatment of isolated systolic hypertension in the elderly led to significant reductions in stroke, myocardial infarction, and all-cause mortality.43 Because HD patients experience acceleration of the aging process, antihypertensive therapy may have a similar beneficial effect among HD patients. In contrast, however, a retrospective cohort analysis of veterans who were older than 80 years and had hypertension demonstrated that among patients whose SBP was judged to be controlled (SBP <140 mmHg), those with higher SBP values were less likely to die than those with lower SBP values.19 Chronic heart failure is another condition for which a higher SBP may be associated with an improved prognosis. Recently, Raphael et al.24 published a meta-analysis that assessed the relationship between SBP and mortality among 80,888 patients with chronic heart failure. A 10-mmHg increase in SBP was associated with decreased mortality (13.0%; 95% CI 10.6 to 15.4%).

This study has several important strengths: (1) Use of an incident cohort, which reduced the likelihood of survivor bias and allowed for longer follow-up time; (2) adjustment for important case-mix determinants; (3) large HD sample representative of the US Renal Data System population except for a slight overrepresentation of black patients, studied under “real-world” conditions, thereby ensuring external validity; (4) an excellent database with <1% of all time-varying covariate values missing; and (5) the consistency of the results regarding effect modification for age and diabetes status on predialysis SBP. The study also has important significant limitations: (1) Like all observational studies, we cannot exclude unidentified covariates, and we cannot infer causality; (2) we lacked reliable comorbidity data on baseline cardiovascular disease and congestive heart failure; and (3) use of routine in-center BP measurements may be inferior to measurement of home BP and ambulatory BP monitoring as a way to assess hypertension control and predict clinical outcomes among HD patients.44–47

In summary, this study demonstrates that the relationships between BP and mortality among HD patients may be influenced by age, race, and diabetes status. In conclusion, a prospective, randomized, controlled trial is required to determine optimum BP targets in subgroups of HD patients. Future Kidney Disease Outcome Quality Initiative (K/DOQI) guidelines may need to consider different BP targets for subgroups of HD patients.

CONCISE METHODS

Study Participants

We studied incident patients who began dialysis at facilities operated by Dialysis Clinic Incorporated (DCI) from January 1, 2000, through December 31, 2006. Inclusion criteria were age ≥20 years at start of HD and patient survival for ≥150 days from the first outpatient HD. We restricted the cohort to patients with ≥150 days of follow up to allow a 30-day lag from the study outcome and to exclude the first 30 days of HD. Exclusion criteria were (1) previous renal transplant or peritoneal dialysis; (2) initiation of long-term HD outside DCI; and (3) missing data on gender, age, or onset of ESRD. Follow-up for death continued until change in modality (renal transplant or peritoneal dialysis), transfer from DCI or withdrawal from dialysis, or study end on December 31, 2007. Patients who transferred from DCI or withdrew from dialysis were followed for vital status for an additional 30 days.

Laboratory and Clinical Parameters

Laboratory measurements were performed monthly at the DCI Laboratory (Nashville, TN). Dialysis dosage, expressed as single-pool Kt/V, was computed using variable-volume urea kinetic modeling.48 Patient age, gender, race, cause of ESRD, and start date of HD were obtained from DCI's computerized medical information system (DARWIN). Laboratory data were transferred electronically into DARWIN, using range checks to ensure quality. The study was conducted using predialysis BP measured with participants in the sitting position in accordance with standard clinical practice. Date and cause of death were obtained from Centers for Medicare and Medicaid Services Death Notification form #2746.

Statistical Analysis

Cox proportional hazards models were constructed to investigate the association between predialysis BP and PP and all-cause mortality. Fixed covariates included gender, race, cause of ESRD, and the age and year of HD initiation. Time-varying covariates, including hemoglobin, albumin, creatinine, dialysis dosage, and postdialysis weight, were defined by quintiles. We used 30- and 90-day lag periods to decrease bias from possible secondary influence of the terminal event. Age, BP, and PP were assessed as continuous variables, centered at their sample medians and divided by 10 to reduce collinearity. These variables were added to analyses as cubic polynomial splines with one to four interior knots to model potentially nonlinear relationships with mortality. Splines with two interior knots fit well without inducing clinically uninterruptable changes in the shape of the hazard functions. Additional models included statistical interactions among BP, age, race, and diabetes status to determine whether these factors modified the relationship between BP and mortality.

BP among younger and older HD patients is not the same49; therefore, graphic summaries of HRs were limited to plausible age and BP combinations defined by the bivariate 5th and 95th percentiles of 90-day BP averages. Data are presented as means ± SD. Statistical analyses were conducted in SAS 9.2 (SAS Institute, Cary, NC).50 Statistical significance was defined as P < 0.05. We used the BIC to evaluate the strength of empirical support for the importance of BP as a risk factor for mortality. The BIC combines information on lack of fit (−2 times the maximized log-likelihood) with a penalty for an increased number of parameters: [number of parameters times log(number of events)]. Smaller BIC values represent greater empirical support for a given model.51,52 We used the difference between the BIC for each model and the model with the smallest BIC to summarize support for each model.

DISCLOSURES

D.M. and P.G.Z. receive salary support via their respective institutions from Dialysis Clinic, Inc.

Acknowledgments

This study was funded in part by Dialysis Clinic Inc., a not-for-profit corporation.

Special thanks to all DCI patients, without whom this study would not have been possible. We thank all DCI facilities and medical directors for collaborative assistance and Candice Welhausen, Kelly Utterback, and Serena Cumber for technical support.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • See related editorial, “Blood Pressure and Mortality among ESRD Patients: All Patients Are Not Created Equal,” on pages 1816–1818.

REFERENCES

  1. 1.↵
    Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 213: 1143–1152, 1970
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Kannel WB
    : Blood pressure as a cardiovascular risk factor: Prevention and treatment. JAMA 275: 1571–1576, 1996
    OpenUrlCrossRefPubMed
  3. 3.↵
    Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 202: 1028–1034, 1967
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Vasan RS,
    2. Larson MG,
    3. Leip EP,
    4. Evans JC,
    5. O'Donnell CJ,
    6. Kannel WB,
    7. Levy D
    : Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 345: 1291–1297, 2001
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Rosendorff C,
    2. Black HR,
    3. Cannon CP,
    4. Gersh BJ,
    5. Gore J,
    6. Izzo JL Jr.,
    7. Kaplan NM,
    8. O'Connor CM,
    9. O'Gara PT,
    10. Oparil S
    : Treatment of hypertension in the prevention and management of ischemic heart disease: A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 115: 2761–2788, 2007
    OpenUrlFREE Full Text
  6. 6.↵
    1. Rosendorff C
    : Hypertension and coronary artery disease: A summary of the American Heart Association scientific statement [published erratum appears in J Clin Hypertens (Greenwich) 9: 976, 2007]. J Clin Hypertens (Greenwich) 9: 790–795, 2007
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Klassen PS,
    2. Lowrie EG,
    3. Reddan DN,
    4. DeLong ER,
    5. Coladonato JA,
    6. Szczech LA,
    7. Lazarus JM,
    8. Owen WF Jr.
    : Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 287: 1548–1555, 2002
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Molander L,
    2. Lovheim H,
    3. Norman T,
    4. Nordstrom P,
    5. Gustafson Y
    : Lower systolic blood pressure is associated with greater mortality in people aged 85 and older. J Am Geriatr Soc 56: 1853–1859, 2008
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Hebert LA,
    2. Kusek JW,
    3. Greene T,
    4. Agodoa LY,
    5. Jones CA,
    6. Levey AS,
    7. Breyer JA,
    8. Faubert P,
    9. Rolin HA,
    10. Wang SR
    : Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. Hypertension 30: 428–435, 1997
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Patel A,
    2. MacMahon S,
    3. Chalmers J,
    4. Neal B,
    5. Woodward M,
    6. Billot L,
    7. Harrap S,
    8. Poulter N,
    9. Marre M,
    10. Cooper M,
    11. Glasziou P,
    12. Grobbee DE,
    13. Hamet P,
    14. Heller S,
    15. Liu LS,
    16. Mancia G,
    17. Mogensen CE,
    18. Pan CY,
    19. Rodgers A,
    20. Williams B
    : Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 370: 829–840, 2007
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Gaede P,
    2. Vedel P,
    3. Parving HH,
    4. Pedersen O
    : Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study. Lancet 353: 617–622, 1999
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Arauz-Pacheco C,
    2. Parrott MA,
    3. Raskin P
    : Hypertension management in adults with diabetes. Diabetes Care 27[Suppl 1]: S65–S67, 2004
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Port FK,
    2. Hulbert-Shearon TE,
    3. Wolfe RA,
    4. Bloembergen WE,
    5. Golper TA,
    6. Agodoa LY,
    7. Young EW
    : Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 33: 507–517, 1999
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Stidley CA,
    2. Hunt WC,
    3. Tentori F,
    4. Schmidt D,
    5. Rohrscheib M,
    6. Paine S,
    7. Bedrick EJ,
    8. Meyer KB,
    9. Johnson HK,
    10. Zager PG
    : Changing relationship of blood pressure with mortality over time among hemodialysis patients. J Am Soc Nephrol 17: 513–520, 2006
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Zager PG,
    2. Nikolic J,
    3. Brown RH,
    4. Campbell MA,
    5. Hunt WC,
    6. Peterson D,
    7. Van Stone J,
    8. Levey A,
    9. Meyer KB,
    10. Klag MJ,
    11. Johnson HK,
    12. Clark E,
    13. Sadler JH,
    14. Teredesai P
    : “U” curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 54: 561–569, 1998
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Williams B,
    2. Lindholm LH,
    3. Sever P
    : Systolic pressure is all that matters. Lancet 371: 2219–2221, 2008
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Bakris GL,
    2. Weir MR,
    3. Shanifar S,
    4. Zhang Z,
    5. Douglas J,
    6. van Dijk DJ,
    7. Brenner BM
    : Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAAL study. Arch Intern Med 163: 1555–1565, 2003
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Agarwal R
    : Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease. Clin J Am Soc Nephrol 4: 830–837, 2009
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Oates DJ,
    2. Berlowitz DR,
    3. Glickman ME,
    4. Silliman RA,
    5. Borzecki AM
    : Blood pressure and survival in the oldest old. J Am Geriatr Soc 55: 383–388, 2007
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Kannel WB,
    2. Wolf PA
    : Framingham Study insights on the hazards of elevated blood pressure. JAMA 300: 2545–2547, 2008
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. van den Hoogen PC,
    2. Feskens EJ,
    3. Nagelkerke NJ,
    4. Menotti A,
    5. Nissinen A,
    6. Kromhout D
    : The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 342: 1–8, 2000
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Mazzuchi N,
    2. Carbonell E,
    3. Fernandez-Cean J
    : Importance of blood pressure control in hemodialysis patient survival. Kidney Int 58: 2147–2154, 2000
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Kovesdy CP,
    2. Trivedi BK,
    3. Kalantar-Zadeh K,
    4. Anderson JE
    : Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease. Nephrol Dial Transplant 21: 1257–1262, 2006
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Raphael CE,
    2. Whinnett ZI,
    3. Davies JE,
    4. Fontana M,
    5. Ferenczi EA,
    6. Manisty CH,
    7. Mayet J,
    8. Francis DP
    : Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart 95: 56–62, 2009
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Foley RN,
    2. Parfrey PS,
    3. Harnett JD,
    4. Kent GM,
    5. Murray DC,
    6. Barre PE
    : Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 49: 1379–1385, 1996
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Dasselaar JJ,
    2. Slart RH,
    3. Knip M,
    4. Pruim J,
    5. Tio RA,
    6. McIntyre CW,
    7. de Jong PE,
    8. Franssen CF
    : Haemodialysis is associated with a pronounced fall in myocardial perfusion. Nephrol Dial Transplant 24: 604–610, 2009
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Hothi DK,
    2. Rees L,
    3. Marek J,
    4. Burton J,
    5. McIntyre CW
    : Pediatric myocardial stunning underscores the cardiac toxicity of conventional hemodialysis treatments. Clin J Am Soc Nephrol 4: 790–797, 2009
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Abate JP,
    2. Blackwell TK
    : Life is short, if sweet. Cell Metab 10: 338–339, 2009
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Ahima RS
    : Connecting obesity, aging and diabetes. Nat Med 15: 996–997, 2009
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Shi Y,
    2. Camici GG,
    3. Luscher TF
    : Cardiovascular determinants of life span. Pflugers Arch 459: 315–324, 2010
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Ishida I,
    2. Hirakata H,
    3. Sugimori H,
    4. Omae T,
    5. Hirakata E,
    6. Ibayashi S,
    7. Kubo M,
    8. Fujishima M
    : Hemodialysis causes severe orthostatic reduction in cerebral blood flow velocity in diabetic patients. Am J Kidney Dis 34: 1096–1104, 1999
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Chobanian AV,
    2. Bakris GL,
    3. Black HR,
    4. Cushman WC,
    5. Green LA,
    6. Izzo JL Jr.,
    7. Jones DW,
    8. Materson BJ,
    9. Oparil S,
    10. Wright JT Jr.,
    11. Roccella EJ
    : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289: 2560–2572, 2003
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Sarnak MJ,
    2. Katz R,
    3. Stehman-Breen CO,
    4. Fried LF,
    5. Jenny NS,
    6. Psaty BM,
    7. Newman AB,
    8. Siscovick D,
    9. Shlipak MG
    : Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 142: 497–505, 2005
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Cushman WC,
    2. Grimm RH Jr.,
    3. Cutler JA,
    4. Evans GW,
    5. Capes S,
    6. Corson MA,
    7. Sadler LS,
    8. Alderman MH,
    9. Peterson K,
    10. Bertoni A,
    11. Basile JN
    : Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99: 44i–55i, 2007
    OpenUrlPubMed
  35. 35.↵
    1. Agodoa L,
    2. Eggers P
    : Racial and ethnic disparities in end-stage kidney failure-survival paradoxes in African-Americans. Semin Dial 20: 577–585, 2007
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Frankenfield DL,
    2. Rocco MV,
    3. Frederick PR,
    4. Pugh J,
    5. McClellan WM,
    6. Owen WF Jr.
    : Racial/ethnic analysis of selected intermediate outcomes for hemodialysis patients: Results from the 1997 ESRD Core Indicators Project. Am J Kidney Dis 34: 721–730, 1999
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Mehrotra R,
    2. Kermah D,
    3. Fried L,
    4. Adler S,
    5. Norris K
    : Racial differences in mortality among those with CKD. J Am Soc Nephrol 19: 1403–1410, 2008
    OpenUrlFREE Full Text
  38. 38.↵
    1. Norris K,
    2. Nissenson AR
    : Race, gender, and socioeconomic disparities in CKD in the United States. J Am Soc Nephrol 19: 1261–1270, 2008
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Parekh RS,
    2. Zhang L,
    3. Fivush BA,
    4. Klag MJ
    : Incidence of atherosclerosis by race in the dialysis morbidity and mortality study: A sample of the US ESRD population. J Am Soc Nephrol 16: 1420–1426, 2005
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Bellasi A,
    2. Veledar E,
    3. Ferramosca E,
    4. Ratti C,
    5. Block G,
    6. Raggi P
    : Markers of vascular disease do not differ in black and white hemodialysis patients despite a different risk profile. Atherosclerosis 197: 242–249, 2008
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Lewington S,
    2. Clarke R,
    3. Qizilbash N,
    4. Peto R,
    5. Collins R
    : Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903–1913, 2002
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Heerspink HJ,
    2. Ninomiya T,
    3. Zoungas S,
    4. de Zeeuw D,
    5. Grobbee DE,
    6. Jardine MJ,
    7. Gallagher M,
    8. Roberta MA,
    9. Cass A,
    10. Neal B,
    11. Perkovic V
    : Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: A systematic review and meta-analysis of randomised controlled trials. Lancet 373: 1–7, 2009
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Perry HM Jr.,
    2. Davis BR,
    3. Price TR,
    4. Applegate WB,
    5. Fields WS,
    6. Guralnik JM,
    7. Kuller L,
    8. Pressel S,
    9. Stamler J,
    10. Probstfield JL
    : Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: The Systolic Hypertension in the Elderly Program (SHEP). JAMA 284: 465–471, 2000
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Agarwal R,
    2. Andersen MJ,
    3. Bishu K,
    4. Saha C
    : Home blood pressure monitoring improves the diagnosis of hypertension in hemodialysis patients. Kidney Int 69: 900–906, 2006
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Agarwal R,
    2. Peixoto AJ,
    3. Santos SF,
    4. Zoccali C
    : Pre- and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure. Clin J Am Soc Nephrol 1: 389–398, 2006
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Agarwal R,
    2. Brim NJ,
    3. Mahenthiran J,
    4. Andersen MJ,
    5. Saha C
    : Out-of-hemodialysis-unit blood pressure is a superior determinant of left ventricular hypertrophy. Hypertension 47: 62–68, 2006
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Agarwal R,
    2. Andersen MJ,
    3. Light RP
    : Location not quantity of blood pressure measurements predicts mortality in hemodialysis patients. Am J Nephrol 28: 210–217, 2007
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Depner TA
    : Introduction: kinetic modeling. Adv Ren Replace Ther 2: 283–286, 1995
    OpenUrlPubMed
  49. 49.↵
    1. Rohrscheib MR,
    2. Myers OB,
    3. Servilla KS,
    4. Adams CD,
    5. Miskulin D,
    6. Bedrick EJ,
    7. Hunt WC,
    8. Lindsey DE,
    9. Gabaldon D,
    10. Zager PG
    : Age-related blood pressure patterns and blood pressure variability among hemodialysis patients. Clin J Am Soc Nephrol 3: 1407–1414, 2008
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    SAS: Statistical Analysis System [Computer program], Cary, NC, SAS Institute, 2007
  51. 51.↵
    1. Akaike H
    : A new look at the statistical model identification. IEEE Trans Automat Contr 19: 716–723, 1974
    OpenUrlCrossRef
  52. 52.↵
    1. Burnham KP,
    2. Anderson DR
    : Model Selection and Multimodel Inference: A Practical Information-Theoretical Approach, 2nd Ed., New York, Springer-Verlag, 2002
Back to top

In this issue

View Selected Citations (0)
Print
Download PDF
Email Article
Citation Tools
Request Permissions
Age, Race, Diabetes, Blood Pressure, and Mortality among Hemodialysis Patients
Orrin B. Myers, Christopher Adams, Mark R. Rohrscheib, Karen S. Servilla, Dana Miskulin, Edward J. Bedrick, Philip G. Zager
JASN Nov 2010, 21 (11) 1970-1978; DOI: 10.1681/ASN.2010010125
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section